CLINICAL ROLE -
Chronic Lymphocytic Leukemia: Considerations for Pharmacists
Drs Anthony Perissinotti and Kirollos Hanna provide some important considerations for pharmacists in treating chronic lymphocytic leukemia.
CAR T for Chronic Lymphocytic Leukemia
Experts discuss the potential future use of CAR T-cell therapy and bispecific therapeutics for chronic lymphocytic leukemia based on data presented at ASH 2021.
Noncovalent Binding BTK Inhibitors for Chronic Lymphocytic Leukemia
Dr Anthony Perissinotti details an effective new therapy on the horizon in chronic lymphocytic leukemia.
Treatment Selection Strategies for Chronic Lymphocytic Leukemia
Anthony Perissinotti and Kirollos Hanna discuss considerations for selecting treatment regimens in chronic lymphocytic leukemia.
Tumor Lysis and Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia experts debate how to prevent or reduce the risk of tumor lysis in patients.
Chronic Lymphocytic Leukemia: Considerations for Anti-CD20 Monoclonal Antibodies
Anthony Perissinotti, PharmD, BCOP, explains potential scenarios requiring anti-CD20 monoclonal antibodies as a therapy for chronic lymphocytic leukemia.
Anti-CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia
Kirollos Hanna, PharmD, BCPS, BCOP, reviews the use of anti-CD20 monoclonal antibodies for treating chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia: The MURANO Study
Key opinion leaders discuss data from the MURANO trial on a fixed-duration therapy for relapsed/refractory chronic lymphocytic leukemia.
ASH 2021: A New Formulation for Acalabrutinib
Dr Anthony Perissinotti explains the new formulation of acalabrutinib for chronic lymphocytic leukemia presented at ASH 2021.
Clinical Trials in Zanubrutinib for Chronic Lymphocytic Leukemia
Dr Kirollos Hanna details clinical trial data on the use of zanubrutinib in treating chronic lymphocytic leukemia.
Second-Generation BTK Inhibitors for Chronic Lymphocytic Leukemia
Kirollos Hanna, PharmD, BCPS, BCOP, discusses clinical trial data for second-generation BTK inhibitors for chronic lymphocytic leukemia.
Treatment Options in Chronic Lymphocytic Leukemia
Anthony Perissinotti, PharmD, BCOP, provides an overview of the available treatment options in chronic lymphocytic leukemia, highlighting the role of first-generation BTK inhibitors.
Advice for Optimizing Treatment Success in CLL
Experts share final thoughts and advice for clinicians in the community to help optimize treatment success in CLL.
Emerging Therapies in CLL
Emerging combination therapies and novel agents being studied as initial therapy for CLL are discussed.
BTKi-Based Vs BCL2i-Based Regimens in CLL
Experts discuss factors and approaches to consider if choosing between a BTKi-based and BCL2i-based regimen for frontline therapy in CLL.
BCL2 Inhibitor in Combination With Anti-CD20 mAb for CLL
Kirollos S. Hanna, PharmD, BCPS, BCOP, discusses data on a BCL2 inhibitor in combination with anti-CD20 monoclonal antibodies in the treatment of CLL.
BTK Inhibitor in Combination With Anti-CD20 mAb for CLL
Taylor M. Weis, PharmD, BCOP, discusses data on a BTK inhibitor in combination with anti-CD20 monoclonal antibodies in the treatment of CLL.
Head-to-Head BTK Inhibitor Data and Cardiovascular Toxicity
Experts discuss the results of a head-to-head trial of ibrutinib versus acalabrutinib in CLL and the cardiovascular toxicity associated with BTK inhibitors.
Toxicity Management for BTK Inhibitors: Pharmacist’s Role
Taylor M. Weis, PharmD, BCOP, discusses the role of pharmacists in toxicity prevention and management with BTK inhibitor therapy in CLL.
Long-Term Data on the Use of BTK Inhibitors in CLL
A review of long-term efficacy and safety data on the use of BTK inhibitor monotherapy in the frontline setting, plus insights from clinical practice.
Therapy Initiation and Treatment Goals in CLL
Experts discuss triggers for initiating therapy in a patient with CLL, in addition to the goals of therapy.
The Impact of COVID-19 on Oncology Pharmacy and Patient Care, Part 1
Medication reconciliation is a critical component of the oncology pharmacistʼs duties that has been performed safely over the phone with the patient, caregiver, and pharmacy with the assistance of electronic health records.
2 Clarke Drive Cranbury, NJ 08512